Medicince introduction including background, function, caution, etc.
Indication For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Side effects Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting,
Mechanisam of Action Lenvatinib is amultikinase inhibitor that interrupts the pathways of VEGFR1,VEGFR2 and VEGFR3.It is used in the treatment of differentiated thyroid cancer (DTC),renal Cell Carcinoma and Hepatocellular Carcinoma (HCC)Indication